Literature DB >> 18381359

Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT) exhibits an inhibitory role on tumorigenesis.

Lana E Kandalaft1, Enrique Zudaire, Sergio Portal-Núñez, Frank Cuttitta, Sonia B Jakowlew.   

Abstract

Differentially expressed nucleolar transforming growth factor-beta1 target (DENTT), also known as testis-specific protein Y-encoded-like (TSPYL-2) and cell division autoantigen-1, is a member of the testis-specific protein Y-encoded (TSPY)/TSPY-L/SET/nucleosome assembly protein-1 superfamily. DENTT is expressed in various tissues including normal human lung. Here, we investigate the involvement of DENTT in cancer promotion and progression. DENTT messenger RNA (mRNA) and protein levels were shown to be markedly downregulated in human and mouse primary tumors and in human tumor cell lines. Overexpression of DENTT in human lung (A549-DENTT) and breast (MCF-7-DENTT) cancer cells resulted in diminished growth potential in anchorage-dependent growth assays and reduced capacity to form colonies under anchorage-independent culture conditions. The migratory potential of A549-DENTT and MCF-7-DENTT cells was reduced when compared with empty vector control cells. Treating human lung cell lines with demethylating agents increased DENTT expression significantly. DENTT expression pattern paralleled that of transforming growth factor-beta1 (TGF-beta1) in normal and malignant tissue and ectopic expression or treatment with TGF-beta1 in lung cancer cells was followed by increased DENTT mRNA and protein levels. Collectively, our results suggest a role for DENTT as a suppressor of the tumorigenic phenotype.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18381359      PMCID: PMC2902398          DOI: 10.1093/carcin/bgn087

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  21 in total

1.  Survey of differentially methylated promoters in prostate cancer cell lines.

Authors:  Yipeng Wang; Qiuju Yu; Ann H Cho; Gaelle Rondeau; John Welsh; Eileen Adamson; Dan Mercola; Michael McClelland
Journal:  Neoplasia       Date:  2005-08       Impact factor: 5.715

2.  Epigenomic profiling reveals novel and frequent targets of aberrant DNA methylation-mediated silencing in malignant glioma.

Authors:  Tae-You Kim; Sheng Zhong; C Robert Fields; Jeong Hoon Kim; Keith D Robertson
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

3.  Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies.

Authors:  William M Gallagher; Orla E Bergin; Mairin Rafferty; Zoë D Kelly; Ilse-Maria Nolan; Edward J P Fox; Aedin C Culhane; Linda McArdle; Mario F Fraga; Linda Hughes; Caroline A Currid; Fiona O'Mahony; Aileen Byrne; Alison A Murphy; Catherine Moss; Susan McDonnell; Raymond L Stallings; Jane A Plumb; Manel Esteller; Robert Brown; Peter A Dervan; David J Easty
Journal:  Carcinogenesis       Date:  2005-06-15       Impact factor: 4.944

4.  Differentially expressed nucleolar TGF-beta1 target (DENTT) shows tissue-specific nuclear and cytoplasmic localization and increases TGF-beta1-responsive transcription in primates.

Authors:  Laurent L Ozbun; Alfredo Martínez; Sonia B Jakowlew
Journal:  Biochim Biophys Acta       Date:  2005-03-22

5.  Antiproliferative autoantigen CDA1 transcriptionally up-regulates p21(Waf1/Cip1) by activating p53 and MEK/ERK1/2 MAPK pathways.

Authors:  Yugang Tu; Weiping Wu; Tieqiao Wu; Zemin Cao; Richard Wilkins; Ban-Hock Toh; Mark E Cooper; Zhonglin Chai
Journal:  J Biol Chem       Date:  2007-02-22       Impact factor: 5.157

6.  Detection of recurrent copy number loss at Yp11.2 involving TSPY gene cluster in prostate cancer using array-based comparative genomic hybridization.

Authors:  Sapna Vijayakumar; Devon C Hall; Xavier T Reveles; Dean A Troyer; Ian M Thompson; Dawn Garcia; Ruihua Xiang; Robin J Leach; Teresa L Johnson-Pais; Susan L Naylor
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 12.701

7.  Transforming growth factor beta 1 null mutation in mice causes excessive inflammatory response and early death.

Authors:  A B Kulkarni; C G Huh; D Becker; A Geiser; M Lyght; K C Flanders; A B Roberts; M B Sporn; J M Ward; S Karlsson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

8.  Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency.

Authors:  B Tang; E P Böttinger; S B Jakowlew; K M Bagnall; J Mariano; M R Anver; J J Letterio; L M Wakefield
Journal:  Nat Med       Date:  1998-07       Impact factor: 53.440

9.  TSPY potentiates cell proliferation and tumorigenesis by promoting cell cycle progression in HeLa and NIH3T3 cells.

Authors:  Shane W Oram; Xing Xing Liu; Tin-Lap Lee; Wai-Yee Chan; Yun-Fai Chris Lau
Journal:  BMC Cancer       Date:  2006-06-09       Impact factor: 4.430

10.  Members of the NAP/SET family of proteins interact specifically with B-type cyclins.

Authors:  D R Kellogg; A Kikuchi; T Fujii-Nakata; C W Turck; A W Murray
Journal:  J Cell Biol       Date:  1995-08       Impact factor: 10.539

View more
  15 in total

1.  Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2.

Authors:  Christine E Eyler; Qiulian Wu; Kenneth Yan; Jennifer M MacSwords; Devin Chandler-Militello; Katherine L Misuraca; Justin D Lathia; Michael T Forrester; Jeongwu Lee; Jonathan S Stamler; Steven A Goldman; Markus Bredel; Roger E McLendon; Andrew E Sloan; Anita B Hjelmeland; Jeremy N Rich
Journal:  Cell       Date:  2011-07-08       Impact factor: 41.582

2.  TSPYL2 is a novel regulator of SIRT1 and p300 activity in response to DNA damage.

Authors:  Martina Magni; Giacomo Buscemi; Lucia Maita; Lei Peng; Siu Yuen Chan; Alessandra Montecucco; Domenico Delia; Laura Zannini
Journal:  Cell Death Differ       Date:  2018-07-26       Impact factor: 15.828

3.  The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants.

Authors:  Yunmin Li; Dong Ji Zhang; Yun Qiu; Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Hum Mol Genet       Date:  2017-03-01       Impact factor: 6.150

4.  TSPYL2 is an essential component of the REST/NRSF transcriptional complex for TGFβ signaling activation.

Authors:  M T Epping; A Lunardi; D Nachmani; M Castillo-Martin; T H Thin; C Cordon-Cardo; P P Pandolfi
Journal:  Cell Death Differ       Date:  2015-01-23       Impact factor: 15.828

Review 5.  iNOS: a potential therapeutic target for malignant glioma.

Authors:  A Jahani-Asl; A Bonni
Journal:  Curr Mol Med       Date:  2013-09       Impact factor: 2.222

6.  TSPYL2 is important for G1 checkpoint maintenance upon DNA damage.

Authors:  Kin Pong Tao; Sze Wan Fong; Zhihong Lu; Yick Pang Ching; Kin Wang Chan; Siu Yuen Chan
Journal:  PLoS One       Date:  2011-06-27       Impact factor: 3.240

7.  The X-linked tumor suppressor TSPX interacts and promotes degradation of the hepatitis B viral protein HBx via the proteasome pathway.

Authors:  Tatsuo Kido; Jing-Hsiung James Ou; Yun-Fai Chris Lau
Journal:  PLoS One       Date:  2011-07-29       Impact factor: 3.240

Review 8.  Roles of the Y chromosome genes in human cancers.

Authors:  Tatsuo Kido; Yun-Fai Chris Lau
Journal:  Asian J Androl       Date:  2015 May-Jun       Impact factor: 3.285

9.  Role of Cell Division Autoantigen 1 (CDA1) in Cell Proliferation and Fibrosis.

Authors:  Ban-Hock Toh; Yugang Tu; Zemin Cao; Mark E Cooper; Zhonglin Chai
Journal:  Genes (Basel)       Date:  2010-09-30       Impact factor: 4.096

10.  TSPY and Male Fertility.

Authors:  Csilla Krausz; Claudia Giachini; Gianni Forti
Journal:  Genes (Basel)       Date:  2010-09-21       Impact factor: 4.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.